Inhibitex has announced that the FDA has granted Aurexis, its humanized monoclonal antibody, fast track designation.
In the Pipeline
December 1, 2004 less than 1 minute read
- Inhibitex has announced that the FDA has granted Aurexis, its humanized monoclonal antibody, fast track designation. Aurexis is being evaluated in a Phase II clinical trial for the first-line treatment of serious hospital-associated Staphylococcus aureus bloodstream infections.
- Favrille has initiated a Phase III clinical trial (FavId-06) evaluating the company’s lead product candidate, FavId. FavId, an active immunotherapy, is being studied as a potential therapy for the treatment of follicular B-cell non-Hodgkin’s lymphoma.
- Cardiome Pharma Corp. has initiated subject dosing in its Phase I study of a controlled release formulation of oral RSD1235, which is being developed as a chronic treatment for atrial fibrillation.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content